[1]成志云,解李祥,白如玉,等.生物碱类化合物降压作用及其机制研究进展[J].华侨大学学报(自然科学版),2023,44(5):550-557.[doi:10.11830/ISSN.1000-5013.202307026]
　CHENG Zhiyun,XIE Lixiang,BAI Ruyu,et al.Research Progress on Antihypertensive Effect and Mechanism of Alkaloid Compounds[J].Journal of Huaqiao University(Natural Science),2023,44(5):550-557.[doi:10.11830/ISSN.1000-5013.202307026]
点击复制

生物碱类化合物降压作用及其机制研究进展()
分享到：

《华侨大学学报（自然科学版）》[ISSN:1000-5013/CN:35-1079/N]

卷:
第44卷
期数:
2023年第5期
页码:
550-557
栏目:
出版日期:
2023-09-20

文章信息/Info

Title:
Research Progress on Antihypertensive Effect and Mechanism of Alkaloid Compounds
文章编号:
1000-5013(2023)05-0550-08
作者:
成志云;  解李祥;  白如玉;  刁勇
华侨大学 医学院, 福建 泉州 362021
Author(s):
CHENG Zhiyun;  XIE Lixiang;  BAI Ruyu;  DIAO Yong
School of Medicine, Huaqiao University, Quanzhou 362021, China
关键词:
高血压;  生物碱;  作用机制;  降压作用
Keywords:
hypertension;  alkaloid;  mechanism of action;  antihypertensive
分类号:
R284.2
DOI:
10.11830/ISSN.1000-5013.202307026
文献标志码:
A
摘要:
作为一种广泛存在于植物体内的活性化合物,生物碱已被证明有显著的降压作用,且作用机制也逐渐被阐明.通过查阅近年来的相关文献,综述各种来源的生物碱在降压领域的研究进展,阐述生物碱在治疗高血压方面的潜力及今后研究需要关注的问题.结果表明:生物碱降压作用显著,作用机制逐渐明确,有望成为治疗高血压的潜力药物.
Abstract:
As an active compound widely presented in plants, alkaloids have been shown to have significant antihypertensive effects, and the mechanism of action is gradually being elucidated. By reviewing relevant literature in recent years, research progress of various sources of alkaloids in the field of hypertension is reviewed, and the potential of alkaloids in the treatment of hypertension and the issues that need to be addressed in future research are elucidated. The results show that alkaloids have a significant antihypertensive effect, and the mechanism of action is gradually becoming clear, which is expected to become a potential drug for treating hypertension.

参考文献/References:

[1] ZHANG Kexin,HUANG Sufang,FENG Danni,et al.Sedentary behavioral studies of young and middle-aged adults with hypertension in the framework of behavioral epidemiology: A scoping review[J].International Journal of Environmental Research and Public Health,2022,19(24):16796.DOI:10.3390/ijerph192416796.
[2] SURED A,SILVA A S,SANCHEZ-MACHADO D I,et al.Hypotensive effects of genistein: From chemistry to medicine[J].Chemico-Biological Interactions,2017,268:37-46.DOI:10.1016/j.cbi.2017.02.012.
[3] 周长征.中药降血压活性成分研究进展[J].内蒙古中医药,2012,31(14):100.DOI:10.16040/j.cnki.cn15-1101.2012.14.049.
[4] RAJBIR K,SARROJ A.Alkaloids-important therapeutic secondary metabolites of plant origin[J].Journal of Critical Reviews,2015,2(3):1-8.
[5] 贺琦,黄玲凤,李忠达,等.HPLC-MS法同时检测多类食品中20种有害生物碱含量[J].闽南师范大学学报(自然科学版),2017,30(3):54-62.DOI:10.16007/j.cnki.issn2095-7122.2017.03.007.
[6] 王增武.中国高血压流行和防治现状[J].中国心血管病研究,2022,20(8):673-678.
[7] 张梅,吴静,张笑,等.2018年中国成年居民高血压患病与控制状况研究[J].中华流行病学杂志,2021,42(10):1780-1789.DOI:10.3760/cma.j.cn112338-20210508-00379.
[8] WIMMER R A,LEOPOLDI A,AICHINGER M,et al.Human blood vessel organoids as a model of diabetic vasculopathy[J].Nature,2019,565(7740):505-510.DOI:10.1038/s41586-018-0858-8.
[9] UNGER T,BORGHI C,CHARCHAR F,et al.2020 international society of hypertension global hypertension practice guidelines[J].Hypertension,2020,38(6):982-1004.DOI:10.1097/HJH.0000000000002453.
[10] MA J,CHEN X.Advances in pathogenesis and treatment of essential hypertension[J].Front Cardiovasc Med,2022,9:1003852.DOI:10.3389/fcvm.2022.1003852.
[11] CHARLES L,TRISCOTT J,DOBBS B.Secondary hypertension: Discovering the underlying cause[J].American Family Physician,2017,96(7):453-461.
[12] TIBAZARWA K B,DAMASCENO A A.Hypertension in developing countries[J].Canadian Journal of Cardiology,2014,30(5):527-533.DOI:10.1016/j.cjca.2014.02.020.
[13] AlDISI S S,ANWAR M A,EID A H.Anti-hypertensive herbs and their mechanisms of action: Part Ⅰ[J].Frontiers in Pharmacology,2016,6:323.DOI:10.3389/fphar.2015.00323.
[14] VISIOLI F.Nutritional support in the pharmacological treatment of metabolic syndrome[J].European Journal of Pharmacology,2011,668:S43-S49.DOI:10.1016/j.ejphar.2011.05.083.
[15] LIU Cuiqing,HUANG Yu.Chinese herbal medicine on cardiovascular diseases and the mechanisms of action[J].Front Pharmacol,2016,7:469.DOI:10.3389/fphar.2016.00469.
[16] SHAITO A,THUAN D T B,PHU H T,et al.Herbal medicine for cardiovascular diseases: Efficacy, mechanisms, and safety[J].Front Pharmacol,2020,11:422.DOI:10.3389/fphar.2020.00422.
[17] TANG Fei,YAN Hongling,WANG Lixia,et al.Review of natural resources with vasodilation: Traditional medicinal plants, natural products, and their mechanism and clinical efficacy[J].Front Pharmacol,2021,12:627458.DOI:10.3389/fphar.2021.627458.
[18] SRINIVASAN P,SMOLKE C D.Biosynthesis of medicinal tropane alkaloids in yeast[J].Nature,2020,585(7826):614-619.DOI:10.1038/s41586-020-2650-9.
[19] TALDAEV A,TEREKHOV R P,MELNIK E V,et al.Insights into the cardiotoxic effects of veratrum lobelianum alkaloids: Pilot study[J].Toxins(Basel),2022,14(7):490.DOI:10.3390/toxins14070490.
[20] MELNIK E V,BELOVA M V,TYURIN I A,et al.Quantitative content parameter in the standardization of veratrum aqua, veratrum lobelianum bernh[J].Drug Development & Registration,2021,10(1):107-113.DOI:10.33380/2305-2066-2021-10-1-107-113.
[21] SEALE J T,MCDOUGAL O M.Veratrum parviflorum: An underexplored source for bioactive steroidal alkaloids[J].Molecules,2022,27(16):5349.DOI:10.3390/molecules27165349.
[22] ZHANG Lishuang,ZHANG Junhua,FENG Rui,et al.Efficacy and safety of berberine alone or combined with statins for the treatment of hyperlipidemia: A systematic review and meta-analysis of randomized controlled clinical trials[J].American Journal of Chinese Medicine,2019,47(4):751-767.DOI:10.1142/S0192415X19500393.
[23] KUMAR A,CHOPRA K E,MUKHERJEE M,et al.Current knowledge and pharmacological profile of berberine: An update[J].European Journal of Pharmacology,2015,761:288-297.DOI:10.1016/j.ejphar.2015.05.068.
[24] LIU Yafei,WANG Huanhuan,GENG Yinhong,et al.Advances of berberine against metabolic syndrome-associated kidney disease: Regarding effect and mechanism[J].Front Pharmacol,2023,14:1112088.DOI:10.3389/fphar.2023.1112088.
[25] ZHANG Gaoxing,LIN Xiufang,SHAO Yijia,et al.Berberine reduces endothelial injury and arterial stiffness in spontaneously hypertensive rats[J].Clinical and Experimental Hypertension,2020,42(3):257-265.DOI:10.1080/10641963.2019.1632339.
[26] MA Yuguang,LIANG Liang,ZHANG Yinbin,et al.Berberine reduced blood pressure and improved vasodilation in diabetic rats[J].Journal of Molecular Endocrinology,2017,59(3):191-204.DOI:10.1530/JME-17-0014.
[27] TIAN Hua,KANG Yuming,GAO Hongli,et al.Chronic infusion of berberine into the hypothalamic paraventricular nucleus attenuates hypertension and sympathoexcitation via the ROS/Erk1/2/iNOS pathway[J].Phytomedicine,2019,52:216-224.DOI:10.1016/j.phymed.2018.09.206.
[28] WANG Zhichao,WU Fang,ZHOU Qianbing,et al.Berberine improves vascular dysfunction by inhibiting trimethylamine-N-oxide via regulating the gut microbiota in angiotensin Ⅱ-induced hypertensive mice[J].Front Microbiol,2022,13:814855.DOI:10.3389/fmicb.2022.814855.
[29] WANG Quanxing,LI Xiakang.Immunosuppressive and anti-inflammatory activities of sinomenine[J].International Immunopharmacology,2011,11(3):373-376.DOI:10.1016/j.intimp.2010.11.018.
[30] JIANG Wei,FAN Weiming,GAO Tianle,et al.Analgesic mechanism of sinomenine against chronic pain[J].Pain Research & Management,2020,2020:1876862.DOI:10.1155/2020/1876862.
[31] ZENG Cheng,SHUAI Yunfei,LI Xin.Meta-analysis of efficacy and safety of sinomenine combined with methotrexate in treatment of rheumatoid arthritis[J].China Journal of Chinese Materia Medica,2021,46(1):214-224.DOI:10.19540/j.cnki.cjcmm.20200322.501.
[32] LI Yueying,LIU Yuntao,YAN Xia,et al.Pharmacological effects and mechanisms of Chinese medicines modulating NLRP3 inflammasomes in ischemic cardio/cerebral vascular disease[J].American Journal of Chinese Medicine,2018,46(8):1727-1741.DOI:10.1142/S0192415X18500878.
[33] ZHANG Mengwan,WANG Xiaohui,SHI Jing,et al.Sinomenine in cardio-cerebrovascular diseases: Potential therapeutic effects and pharmacological evidences[J].Frontiers in Cardiovascular Medicine,2021,8:749113.DOI:10.3389/fcvm.2021.749113.
[34] MATSUMOTO T,KOBAYASHI T,ISHIDA K,et al.Vasodilator effect of cassiarin A, a novel antiplasmodial alkaloid from cassia siamea, in rat isolated mesenteric artery[J].Biological & Pharmaceutical Bulletin,2010,33(5):844-848.DOI:10.1248/bpb.33.844.
[35] KOFFI C,SOLETI R,NITIEMA M,et al.Ethanol extract of leaves of cassia siamea lam protects against diabetes-induced insulin resistance, hepatic, and endothelial dysfunctions in ob/ob mice[J].Oxidative Medicine and Cellular Longevity,2019,2019:6560498.DOI:10.1155/2019/6560498.
[36] LAN Yulong,ZHOU Junjun,LIU Jing,et al.Uncaria rhynchophylla ameliorates Parkinson’s disease by inhibiting HSP90 expression: Insights from quantitative proteomics[J].Int J Exp Cell Physiol Biochem Pharmacol,2018,47(4):1453-1464.DOI:10.1159/000490837.
[37] LIANG Jiahao,LUAN Zhilin,TIAN Xiangge,et al.Uncarialins A-Ⅰ, monoterpenoid indole alkaloids from Uncaria rhynchophylla as natural agonists of the 5-HT1A receptor[J].Journal of Natural Products,2019,82(12):3302-3310.DOI:10.1021/acs.jnatprod.9b00532.
[38] WANG Yali,DONG Peipei,LIANG Jiahao,et al.Phytochemical constituents from Uncaria rhynchophylla in human carboxylesterase 2 inhibition: Kinetics and interaction mechanism merged with docking simulations[J].Phytomedicine,2018,51:120-127.DOI:10.1016/j.phymed.2018.10.006.
[39] XIE Zhuqing,TIAN Xiaoting,ZHENG Yueming,et al.Antiepileptic geissoschizine methyl ether is an inhibitor of multiple neuronal channels[J].Acta Pharmacologica Sinica,2020,41(5):629-637.DOI:10.1038/s41401-019-0327-4.
[40] YUN Weijing,ZANG Xinyue,LIU Tiantian,et al.The inhibition effect of uncarialin A on voltage-dependent L-type calcium channel subunit alpha-1C: Inhibition potential and molecular stimulation[J].International Journal of Biological Macromolecules,2020(1):159-168.DOI:10.1016/j.ijbiomac.2020.05.100.
[41] CHANDRA S,SAKLANI S,KUMAR P,et al.Nutraceuticals: Pharmacologically active potent dietary supplements[J].Biomed Research International,2022,2022:2051017.DOI:10.1155/2022/2051017.
[42] SHIRANI F,FOSHATI S,TAVASSOLY M,et al.The effect of capsaicin/red pepper on blood pressure and heart rate: A systematic review and meta-analysis of clinical trials[J].Phytotherapy Research,2021,35(11):6080-6088.DOI:10.1002/ptr.7217.
[43] HE Tianchao,WANG Meichen,TIAN Zixing,et al.Sex-dependent difference in the association between frequency of spicy food consumption and risk of hypertension in Chinese adults[J].European Journal of Nutrition,2019,58(6):2449-2461.DOI:10.1007/s00394-018-1797-8.
[44] PORSZASZ J,GYORGY L,PORZASZ-GIBISZER K.Cardiovascular and respiratory effects of capsaicin[J].Acta Physiol Acad Sci Hung,1955,8(1):61-76.
[45] MAKARA G B,GYORGY L,MOINAR J.Circulatory and respiratory responses to capsaicin, 5-hydroxytryptamine and histamine in rats pretreated with capsaicin[J].Arch Int Pharmacodyn,1967,170:39-45.
[46] TODA N,USUI H,NISHINO N,et al.Cardiovascular effects of capsaicin in dogs and rabbits[J].Journal of Pharmacology and Experimental Theraperapeutics,1972,181:512-521.
[47] TORRES-NARVAREZ J C,MONDRAGON L D,LOPEZ E V,et al.Role of the transient receptor potential vanilloid type 1 receptor and stretch-activated ion channels in nitric oxide release from endothelial cells of the aorta and heart of the rats[J].Experimental and Clinical Cardiology,2012,17(3):89-94.
[48] CHEN L,KASSMAN M,SENDESKI M,et al.Functional transient receptor potential vanilloid 1 and transient receptor potential vanilloid 4 channels along different segments of the renal vasculature[J].Acta Physiol,2015,213(2):481-491.DOI:10.1111/apha.12355.
[49] LI Li,MA Liqun,LUO Zhidan,et al.Lack of TRPV1 aggravates obesity-associated hypertension through the disturbance of mitochondrial Ca2+ homeostasis in brown adipose tissue[J].Hypertension Research,2022,45(5):789-801.DOI:10.1038/s41440-021-00842-8.
[50] HAO Xinzhong,CHEN Jing,LUO Zhidan,et al.TRPV1 activation prevents high-salt diet-induced nocturnal hypertension in mice[J].Pflügers Archiv European Journal of Physiology,2011,461(3):345-353.DOI:10.1007/s00424-011-0921-x.
[51] SZALLASI A.The vanilloid(capsaicin)receptor TRPV1 in blood pressure regulation: A novel therapeutic target in hypertension?[J].International Journal of Molecular Sciences,2023,24(10):8769.DOI:10.3390/ijms2410 8769.
[52] GORGANI L,MOHAMMADI M,NAJAFPOUR G D,et al.Piperine—the bioactive compound of black pepper: From isolation to medicinal formulations[J].Comprehensive Reviews in Food Science and Food Safety,2017,16(1):124-140.DOI:10.1111/1541-4337.12246.
[53] AZIZ N S,SOFIANO-SENG N,MOHD R N S, et al.A review on conventional and biotechnological approaches in white pepper production[J].Journal of the Science of Food and Agriculture,2019,99(6):2665-2676.DOI:10.1002/jsfa.9481.
[54] TAKOOREE H,AUMEERUDDY M Z,RENGASAMY K R R,et al.A systematic review on black pepper(Piper nigrum L.): From folk uses to pharmacological applications[J].Critical Reviews in Food Science and Nutrition,2019,59:S210-S243.DOI:10.1080/10408398.2019.1565489.
[55] TRIPATHI A K,RAY A K,MISHRA S K.Molecular and pharmacological aspects of piperine as a potential molecule for disease prevention and management: Evidence from clinical trials[J].Beni-Suef University Journal of Basic and Applied Sciences,2022,11(1):16.DOI:10.1186/s43088-022-00196-1.
[56] BOORANASUBKAJORN S,HUABPRASERT S,WATTANARANGSAN J,et al.Vasculoprotective and vasodilatation effects of herbal formula(Sahatsatara)and piperine in spontaneously hypertensive rats[J].Phytomedicine,2017,24:148-156.DOI:10.1016/j.phymed.2016.11.013.
[57] SIRSJO A,SODERKVIST P,SUNDQVIST T,et al.Different induction mechanisms of mRNA for inducible nitric oxide synthase in rat smooth muscle cells in culture and in aortic strips[J].FEBS Letters,1994,338(2):191-196.DOI:10.1016/0014-5793(94)80363-3.
[58] GEWALTIG M,KOJDA G.Vasoprotection by nitric oxide: Mechanisms and therapeutic potential[J].Cardiovasc Res,2002,55(2):250-260.DOI:10.1016/S0008-6363(02)00327-9.
[59] KREUTZ R,ALGHARABLY E A E,AZIZI M,et al.Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: Implications for COVID-19 [J].Cardiovascular Research,2020,16(10):1688-1699.DOI:10.1093/cvr/cvaa097.
[60] MAITI S,BANERJEE A,KANWAR M.In silico Nigellidine(N.sativa)bind to viral spike/active-sites of ACE1/2,AT1/2 to prevent COVID-19 induced vaso-tumult/vascular-damage/comorbidity[J].Vascul Pharmacol,2021,138:106856.DOI:10.1016/j.vph.2021.106856.
[61] ZONG Qunchuan,MA Guangyi,WANG Tao.Uric acid lowering improves insulin sensitivity and lowers blood pressure: A meta-analysis of randomized parallel-controlled clinical trials[J].African Health Sciences,2021,21(1):82-95.DOI:10.4314/ahs.v21i1.13.
[62] FEIG D I,SOLETSKY B,JOHNSON R J.Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial[J].Jama-Journal of the American Medical Association,2008,300(8):924-932.DOI:10.1001/jama.300.8.924.
[63] YU M A,SANCHEZ-LOZADA L G,JOHNSON R J,et al.Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction[J].Journal of Hypertension,2010,28(6):1234-1242.DOI:10.1097/HJH.0b013e328337da1d.
[64] SOUTH A M,SHALTOUT H A,NIXO P A,et al.Association of circulating uric acid and angiotensin-(1-7)in relation to higher blood pressure in adolescents and the influence of preterm birth[J].Journal of Human Hypertension,2020,34(12):818-825.DOI:10.1038/s41371-020-0335-3.
[65] SOUTH A M,SHALTOUT H A,WASHBURN L K,et al.Fetal programming and the angiotensin-(1-7)axis: A review of the experimental and clinical data[J].Clinical Science,2019,133(1):55-74.DOI:10.1042/CS20171550.
[66] GRAYSON P C,KIM S Y,LA V M,et al.Hyperuricemia and incident hypertension: A systematic review and meta-analysis[J].Arthritis Care Res(Hoboken).2010,63(1):102-110.DOI:10.1002/acr.20344.
[67] MCMULLAN C J,BORGI L,FISHER N,et al.Effect of uric acid lowering on renin-angiotensin-system activation and ambulatory BP: A randomized controlled trial[J].Clinical Journal of the American Society of Nephrology,2017,12(5):807-816.DOI:10.2215/CJN.10771016.

备注/Memo

备注/Memo:
收稿日期: 2023-07-02
通信作者: 刁勇(1967-),男,教授,博士,博士生导师,主要从事基因药物的研究.E-mail:diaoyong@hqu.edu.cn.
基金项目: 国家自然科学基金资助项目(20141ZA003); 福建省药理学会科技联合项目(2021FJYL007)
更新日期/Last Update: 2023-09-20